Based on these data, the Food and Drug Administration (FDA) approved durvalumab as a new SoC regardless PD-L1 expression in February 2018, whereas the EMA approval in September 2018 was limited to tumours with PD-L1 ≥ 1%. The gene discussed is CD274; the disease is neoplasm.